Skip to main content

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH

Written by Customer Service on . Posted in Mergers And Acquisitions.

Dosimetry portfolio strengthened with Medical Imaging QA and AI validation 

Louvain-la-Neuve, Belgium, 03 November 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance.

Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, with support from Charité University Hospital in Berlin, PhantomX is a recognized leader in the development of realistic anthropomorphic phantoms. The company’s proprietary advanced quality assurance technologies are used globally for validating diagnostic and therapeutic imaging systems, as well as medical education and training. PhantomX is at the forefront of quality assurance for AI applications in medical imaging and provides tools for AI-enhanced clinical solutions. 

“PhantomX’s expertise in AI validation perfectly complements IBA’s portfolio of Clinical Workflow Solutions in Radiation Therapy and Medical Imaging,” said Jean-Marc Bothy, President of IBA Dosimetry. “Together, we will accelerate innovation in our Medical Imaging Business Line with simulation and AI-driven technologies, delivering greater value to clinicians and patients worldwide.”

Dr. Paul Jahnke, one of the Founders of PhantomX, added: “This merger empowers us to bring our technology to new markets and contribute to the future of intelligent, safe, and effective medical solutions.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

For further information, please contact:

IBA Investor Relations
Thomas Pevenage
+32 10 475 890
investorrelations@iba-group.com		IBA Corporate Communication
Olivier Lechien
+32 10 475 890
communication@iba-group.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.